REG - Oncimmune Hldgs PLC - Director/PDMR Shareholding
11/11/2024 11:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241111:nRSK7323La&default-theme=true
RNS Number : 7323L Oncimmune Holdings PLC 11 November 2024
For immediate release
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Director/PDMR Shareholding
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company
providing research services to the pharmaceutical and biotechnology industries
to enable the delivery of precision medicine, announces the acquisition of
Subscription Shares by certain board members, and waiver and issue of share
options to certain Persons Discharging Managerial Responsibilities pursuant to
the Fundraising, as detailed in the Company's announcement dated 18 October
2024 (the "Fundraising Announcement"). A summary of the subscribing
Directors' shareholdings are as follows:
Subscription for ordinary shares
PDMR Previous holding of Ordinary Shares Number of Subscription Shares purchased Resultant shareholding Resulting % of Enlarged Share Capital
Alistair Macdonald 55,555 100,000 155,555 0.14
Martin Gouldstone 36,023 66,667 102,690 0.09
John Goold 1,150,000 333,333 1,483,333 1.33
Waiver of options
PDMR Number of options waived Date of grant of options waived Exercise price of options waived Resulting number of options held
Martin Gouldstone 589,971 7 November 2023 £0.1695 0
Martin Hudson 105,263 8 December 2023 £0.266 0
Grant of options
PDMR Number of options granted Exercise price % of Enlarged Share Capital
Martin Gouldstone 5,588,661 £0.15 5%
Martin Hudson 3,353,197 £0.15 3%
The new options are subject to performance conditions relating to the
Company's EBITDA and share price performance, further detail of which is set
out in the Fundraising Announcement.
Unless otherwise defined, all capitalised terms used but not defined in this
announcement shall have the meaning given to them in the announcement of the
Fundraising made by the Company on 18 October 2024.
For further information:
Oncimmune Holdings plc
contact@oncimmune.com (mailto:contact@oncimmune.com)
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000
The notifications set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Alistair Macdonald
1. Reason for the notification
a) Position/status: Chairman
b) Initial notification/Amendment: Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Oncimmune Holdings plc
b) LEI: 213800HCYIWT6YPI1I02
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code: GB00BYQ94H38
b) Nature of the transaction: Purchase of new ordinary shares
c) Price(s) and volume(s):
Price(s) Volume(s)
15.0 pence 100,000
d) Aggregated information: Single transaction as in 3 c) above
· Aggregated volume:
· Aggregated Price:
e) Date of the transaction: 23 October 2024
f) Place of the transaction: AIM, London Stock Exchange (XLON)
d)
Aggregated information:
· Aggregated volume:
· Aggregated Price:
Single transaction as in 3 c) above
e)
Date of the transaction:
23 October 2024
f)
Place of the transaction:
AIM, London Stock Exchange (XLON)
1. Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Martin Gouldstone
1. Reason for the notification
a) Position/status: Chief Executive Officer
b) Initial notification/Amendment: Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Oncimmune Holdings plc
b) LEI: 213800HCYIWT6YPI1I02
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code: GB00BYQ94H38
b) Nature of the transaction: Purchase of new ordinary shares
c) Price(s) and volume(s):
Price(s) Volume(s)
15.0 pence 66,667
d) Aggregated information: Single transaction as in 3 c) above
· Aggregated volume:
· Aggregated Price:
e) Date of the transaction: 23 October 2024
f) Place of the transaction: AIM, London Stock Exchange (XLON)
d)
Aggregated information:
· Aggregated volume:
· Aggregated Price:
Single transaction as in 3 c) above
e)
Date of the transaction:
23 October 2024
f)
Place of the transaction:
AIM, London Stock Exchange (XLON)
1. Details of the person discharging managerial responsibilities/person closely
associated
a) Name: John Goold
1. Reason for the notification
a) Position/status: Non-Executive Director
b) Initial notification/Amendment: Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Oncimmune Holdings plc
b) LEI: 213800HCYIWT6YPI1I02
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code: GB00BYQ94H38
b) Nature of the transaction: Purchase of new ordinary shares
c) Price(s) and volume(s):
Price(s) Volume(s)
15.0 pence 333,333
d) Aggregated information: Single transaction as in 3 c) above
· Aggregated volume:
· Aggregated Price:
e) Date of the transaction: 23 October 2024
f) Place of the transaction: AIM, London Stock Exchange (XLON)
d)
Aggregated information:
· Aggregated volume:
· Aggregated Price:
Single transaction as in 3 c) above
e)
Date of the transaction:
23 October 2024
f)
Place of the transaction:
AIM, London Stock Exchange (XLON)
1. Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Martin Gouldstone
1. Reason for the notification
a) Position/status: Chief Executive Officer
b) Initial notification/Amendment: Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Oncimmune Holdings plc
b) LEI: 213800HCYIWT6YPI1I02
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code: GB00BYQ94H38
b) Nature of the transaction: Waiver of options
c) Price(s) and volume(s):
Price(s) Volume(s)
16.95 pence 589,971
d) Aggregated information: Single transaction as in 3 c) above
· Aggregated volume:
· Aggregated Price:
e) Date of the transaction: 8 November 2024
f) Place of the transaction: Outside a trading venue
d)
Aggregated information:
· Aggregated volume:
· Aggregated Price:
Single transaction as in 3 c) above
e)
Date of the transaction:
8 November 2024
f)
Place of the transaction:
Outside a trading venue
1. Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Martin Hudson
1. Reason for the notification
a) Position/status: Finance Director
b) Initial notification/Amendment: Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Oncimmune Holdings plc
b) LEI: 213800HCYIWT6YPI1I02
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code: GB00BYQ94H38
b) Nature of the transaction: Waiver of options
c) Price(s) and volume(s):
Price(s) Volume(s)
26.6 pence 105,263
d) Aggregated information: Single transaction as in 3 c) above
· Aggregated volume:
· Aggregated Price:
e) Date of the transaction: 8 November 2024
f) Place of the transaction: Outside a trading venue
d)
Aggregated information:
· Aggregated volume:
· Aggregated Price:
Single transaction as in 3 c) above
e)
Date of the transaction:
8 November 2024
f)
Place of the transaction:
Outside a trading venue
1. Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Martin Gouldstone
1. Reason for the notification
a) Position/status: Chief Executive Officer
b) Initial notification/Amendment: Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Oncimmune Holdings plc
b) LEI: 213800HCYIWT6YPI1I02
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code: GB00BYQ94H38
b) Nature of the transaction: Grant of options
c) Price(s) and volume(s):
Price(s) Volume(s)
15 pence 5,588,661
d) Aggregated information: Single transaction as in 3 c) above
· Aggregated volume:
· Aggregated Price:
e) Date of the transaction: 8 November 2024
f) Place of the transaction: Outside a trading venue
d)
Aggregated information:
· Aggregated volume:
· Aggregated Price:
Single transaction as in 3 c) above
e)
Date of the transaction:
8 November 2024
f)
Place of the transaction:
Outside a trading venue
1. Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Martin Hudson
1. Reason for the notification
a) Position/status: Finance Director
b) Initial notification/Amendment: Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Oncimmune Holdings plc
b) LEI: 213800HCYIWT6YPI1I02
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code: GB00BYQ94H38
b) Nature of the transaction: Grant of options
c) Price(s) and volume(s):
Price(s) Volume(s)
15 pence 3,353,197
d) Aggregated information: Single transaction as in 3 c) above
· Aggregated volume:
· Aggregated Price:
e) Date of the transaction: 8 November 2024
f) Place of the transaction: Outside a trading venue
d)
Aggregated information:
· Aggregated volume:
· Aggregated Price:
Single transaction as in 3 c) above
e)
Date of the transaction:
8 November 2024
f)
Place of the transaction:
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFFLFFZFLFFBERecent news on Oncimmune Holdings
See all newsREG - AIM Oncimmune Hldgs PLC - Cancellation - ONCIMMUNE HOLDINGS PLC
AnnouncementREG - Oncimmune Hldgs PLC - Appointment of Administrators & Nomad Resignation
AnnouncementREG - Oncimmune Hldgs PLC - Holding(s) in Company
AnnouncementREG - FTSE Russell - Oncimmune Holdings
AnnouncementREG - AIM Oncimmune Hldgs PLC - Suspension - Oncimmune Holdings Plc
Announcement